BTM-3528

N/A

Report date: 2022/06/10 09:38:09
NME

Base Information

Drug NameBTM-3528
Drug Alias NameBTM-3528
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin D1 inhibitorsCaspase-3 activatorsApoptosis inducers
TargetsCyclin D1Caspase-3
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBantam Pharmaceuticals LLC
China Registration ClassN/A

Develop Information

Active CompaniesBantam Pharmaceuticals LLC
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A